Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report)'s stock price traded down 5.4% during mid-day trading on Monday . The company traded as low as $0.95 and last traded at $0.96. 2,831,795 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 22,142,797 shares. The stock had previously closed at $1.01.
Analyst Ratings Changes
A number of research analysts have recently issued reports on the company. The Goldman Sachs Group dropped their target price on Ginkgo Bioworks from $1.25 to $1.10 and set a "sell" rating on the stock in a report on Monday, January 22nd. TD Cowen dropped their target price on Ginkgo Bioworks from $7.00 to $3.00 and set an "outperform" rating on the stock in a report on Friday, March 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $2.20.
Read Our Latest Stock Report on DNA
Ginkgo Bioworks Price Performance
The stock has a market capitalization of $2.05 billion, a PE ratio of -2.03 and a beta of 1.36. The stock has a 50 day moving average of $1.23 and a two-hundred day moving average of $1.39.
Ginkgo Bioworks (NYSE:DNA - Get Free Report) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.01). Ginkgo Bioworks had a negative net margin of 355.08% and a negative return on equity of 48.23%. The business had revenue of $34.76 million during the quarter, compared to analysts' expectations of $40.37 million. During the same quarter last year, the firm earned ($0.04) earnings per share. The firm's quarterly revenue was down 64.6% compared to the same quarter last year. As a group, research analysts predict that Ginkgo Bioworks Holdings, Inc. will post -0.32 earnings per share for the current fiscal year.
Insider Activity at Ginkgo Bioworks
In other Ginkgo Bioworks news, insider Mark E. Dmytruk sold 51,169 shares of the business's stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $1.05, for a total transaction of $53,727.45. Following the sale, the insider now directly owns 865,079 shares in the company, valued at $908,332.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Ginkgo Bioworks news, insider Mark E. Dmytruk sold 39,569 shares of the business's stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $1.21, for a total transaction of $47,878.49. Following the sale, the insider now directly owns 761,737 shares in the company, valued at $921,701.77. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Mark E. Dmytruk sold 51,169 shares of the business's stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $1.05, for a total value of $53,727.45. Following the sale, the insider now owns 865,079 shares in the company, valued at $908,332.95. The disclosure for this sale can be found here. Company insiders own 15.05% of the company's stock.
Institutional Trading of Ginkgo Bioworks
A number of institutional investors have recently bought and sold shares of DNA. Spire Wealth Management purchased a new stake in shares of Ginkgo Bioworks in the fourth quarter valued at $25,000. Creative Planning purchased a new stake in shares of Ginkgo Bioworks in the fourth quarter valued at $25,000. Silverlake Wealth Management LLC purchased a new stake in shares of Ginkgo Bioworks in the fourth quarter valued at $25,000. Private Advisor Group LLC purchased a new stake in shares of Ginkgo Bioworks in the first quarter valued at $26,000. Finally, Aspen Grove Capital LLC purchased a new stake in shares of Ginkgo Bioworks in the first quarter valued at $27,000. 78.63% of the stock is currently owned by hedge funds and other institutional investors.
About Ginkgo Bioworks
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Featured Articles
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
